No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

[2] An increased understanding of how cells within these areas undergo transformation is crucial for improving the early detection and treatment of lung cancer. Surrounding these epithelial cells ...

Xilio Therapeutics (XLO) announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane ...

A New Ventilator-on-a-Chip Model to Study Lung Damage Sep. 19, 2024 — Scientists are now able to directly compare the different kinds of injury that mechanical ventilation causes to cells in the ...

Endometriosis, a prevalent gynecological condition, is characterized by the growth of endometrial-like tissues outside the ...

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEM ...

The following highlights showcase the most pivotal, innovative research published across multiple therapeutic areas in ...

AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...